Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 5Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Sarcoma, Alveolar Soft Part 1Recurrence 1Papillomavirus Infections 1Lymphoma 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma in Situ 1

Interventions

Carboplatin 235Pemetrexed 214Paclitaxel 160Cisplatin 150pembrolizumab 145Erlotinib Hydrochloride 141Docetaxel 133Gemcitabine 94Bevacizumab 85Nivolumab 72Radiotherapy 62atezolizumab 40Radiosurgery 37Afatinib 37osimertinib 35130-nm albumin-bound paclitaxel 35Cetuximab 34durvalumab 33Ipilimumab 32Gefitinib 31Albumin-Bound Paclitaxel 29Vinorelbine 23Taxes 22Etoposide 20Crizotinib 19Radiation 17Sorafenib 16Cyclophosphamide 16Dexamethasone 15Magnetic Resonance Spectroscopy 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Non-Small-Cell Lung × Loperamide × Clear all
NCT01814553 2016-10-31

ADAM-Afatinib Diarrhea Assessment and Management

Boehringer Ingelheim

Phase 3 Completed
40 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡